Spravato Access And Reimbursement Guide

Getting Spravato Approved Is a Paperwork Gauntlet

Most people asking about Spravato (esketamine, brand name Spravato) don't realize it's one of the most administratively complex psychiatric treatments available. The drug itself is straightforward — it's a nasal spray administered under clinical observation. What's not straightforward is getting a patient to actually receive it and getting paid for it. I spent two years working the access and reimbursement side for a multi-site mental health clinic. We treated depression. Spravato became a regular part of our practice around 2020. Here's what actually happens when you try to navigate it.

Spravato Access And Reimbursement Guide

Before we get into the nitty-gritty, let me be clear: Spravato has a Risk Evaluation and Mitigation Strategy (REMS) certification requirement. Both the prescribing provider and the administering site must be REMS-certified. This isn't optional. The drug won't ship to a clinic that isn't enrolled in the program. For reimbursement, there are a few key codes you need to know. The drug itself is billed under a J-code. As of my last update, J3490 was being used with the appropriate quantity notation, but payers sometimes require the exact unit-to-dose calculation. A standard dose is one 28 mg or 42 mg spray device per nostril, depending on the dosing step. You bill per device used. Getting this wrong is the most common claim denial reason I see. The administration CPT code is 90791 when combined with psychotherapy, or you may use 96368 for the intranasal administration separately. Some payers bundle this differently. Your mileage will vary by plan. That's the thing about Spravato billing — there is no single playbook. Medicare covers it. Most commercial plans cover it after the FDA approval and subsequent coverage decisions. But Medicaid? That's a different conversation entirely. Some states cover it. Most don't. I had a patient in a state where the Medicaid program explicitly excluded it, and the only path was a charitable assistance application through the manufacturer's program.

Here's a practical tip that saved us countless hours: build a prior authorization (PA) template that includes the specific DSM-5 diagnosis code, documentation of failed antidepressant trials, and a letter of medical necessity written in the language payers respond to. Most initial PAs get denied on technicalities — missing ICD-10 specificity, no documented trial duration, or the wrong form. A well-prepared first submission from us went through on the first attempt roughly 70% of the time. That's not amazing, but it's better than the average clinic's first-attempt acceptance rate. The SPRavato Patient Assistance Program (connected to Janssen, the manufacturer) can cover copays for commercially insured patients and full cost for qualifying uninsured or underinsured patients. Enrolling a patient here usually takes about 10 minutes of form-filling if you have their income information and insurance details upfront. We kept a standing packet at registration. Patients who came in without documentation got sent home and rescheduled, which cost us appointment slots and frustrated everyone. One edge case that still bugs me: a patient whose insurance denied Spravato because the PA listed "treatment-resistant depression" as the indication, but their policy required documentation of at least four adequate antidepressant trials. The prescriber had only documented three. We appealed with a fourth trial added from old records we pulled from the chart. The appeal took six weeks. The patient was on a waiting list for treatment at the time. This is why thorough pretreatment documentation matters. If your clinical workflow doesn't capture every medication trial with start date, end date, dose, and reason for discontinuation, you're going to have this problem.

Another thing nobody tells you: Spravato requires two hours of post-dose monitoring in the clinic. You cannot bill for time that isn't spent in the facility. Some clinics try to stretch the observation window or combine it with other services. Don't. The REMS program monitors adherence, and payers audit documentation. We lost a claim review once because our timestamps didn't align with the administration record. It was a minor administrative error, not fraud, but it still resulted in a denied claim and a paperwork headache that took three staff-hours to resolve. For self-pay patients, the list price is steep. The manufacturer's assistance program is the primary route most clinics use. Without it, very few patients can sustain the treatment long-term. The induction phase alone — twice weekly for four weeks — represents eight clinic visits. Maintenance is once weekly or biweekly. The math on out-of-pocket costs is brutal without assistance. If you're setting up a Spravato program from scratch, budget six to eight weeks for REMS certification, another two to three weeks to get your payer enrollment sorted, and plan for a steep learning curve on the first fifty claims. They won't all go through clean. You'll learn which payers have quirks, which forms they prefer, and which denial codes show up repeatedly. Track your denial reasons. That's the single most useful thing you can do.

Some clinics add a care coordination fee or a monthly management fee on top of the drug and procedure codes. This is legal in some cases, but you need to disclose it clearly and check with your contracts. A few payers flag unbundled management fees as suspicious. Read your payer manuals before you add new line items. There's also the issue of treatment failure pathways. Once a patient completes the induction phase, if they're not responding, some payers require documented step-down or alternative treatment before authorizing continued Spravato. Others auto-approve through the maintenance phase. Again, it depends on the plan. Keep a matrix of your top ten payers and their Spravato policies. Update it quarterly. Insurance language changes frequently. The bottom line: Spravato is clinically effective for the right patients. The access and reimbursement process is not. It requires systems, patience, and a willingness to deal with denial appeals as a normal part of the workflow. If your clinic isn't prepared for that, consider whether the volume of eligible patients justifies the administrative overhead.